Clinical trial
Study of Long-term Antibody Persistence After a Booster Dose of Menitorix…
NCT00454987 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00454987 |
|---|---|
| Title | Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine |
| Official title | Assessment of Long-term Antibody Persistence After a Booster Dose of GSK Biologicals' Hib & Meningococcal C Vaccine (Menitorix™) 811936 Given at 12-15 Months of Age to Subjects Primed With 3 Doses of Menitorix™ at 2, 3, 4 Months of Age |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Haemophilus Influenzae Type b, Neisseria Meningitidis, Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine |
| Intervention type | Biological |
| Interventions | Menitorix, Infanrix IPV |
| Enrollment | 288 |
| Start date | May 16, 2007 |
| Primary completion | Oct 12, 2007 |
| Completion | Oct 12, 2007 |
| First posted | Apr 2, 2007 |
| Last update posted | Jun 16, 2020 |
| Countries | Poland, United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: